Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Malignant Solid Neoplasm 1Inflammatory Breast Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Advanced Breast Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 18Trastuzumab 16Paclitaxel 15Taxes 11Doxorubicin 11Radiotherapy 7Lapatinib 6Albumin-Bound Paclitaxel 6Vorinostat 5Tamoxifen 5Docetaxel 5Carboplatin 5Capecitabine 5Bevacizumab 5Radiation 4Letrozole 4Immunohistochemistry 4Anastrozole 4sargramostim 3pegfilgrastim 3exemestane 3Magnetic Resonance Spectroscopy 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Flow Cytometry 3Filgrastim 3Chemotherapy, Adjuvant 3saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms, Male × PF-05280014 × Clear all
NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
305 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡